EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 593 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 How to Spend Time with Friends and Family Now that COVID... August 13, 2020 Jennifer Garner Shared A Video Of Her Mammogram Appointment October 21, 2019 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Load more HOT NEWS Man Met A Stranger At A Bar Who Was In Need... New on NCI Websites for October 2018 FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival
